Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2014
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide; Fludarabine; MART-1-specific T lymphocyte therapy
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 23 Dec 2011 New trial record